The TRAIL of oncogenes to apoptosis

BioFactors

Volumn 39, Issue 4, 2013, Pages 343-354

  Oikonomou, Eftychia ^a   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Apoptosis; Cancer therapy; Kinase inhibitors; RAS oncogenes; TRAIL

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; B RAF KINASE INHIBITOR; BORTEZOMIB; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN INHIBITOR; LEXATUMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAPATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN BCL 2 INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; QUERCETIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOL ACETATE; TANESPIMYCIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE; ONCOGENE MYC; ONCOGENE NEU; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84881666221     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1112     Document Type: Review

References (116)

1. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., et al. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
2. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W.S., Huang, C. P., et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
3. Schneider, P., Bodmer, J. L., Thome, M., Hofmann, K., Holler, N., et al. (1997) Characterization of two receptors for TRAIL. FEBS Lett. 416, 329-334.
4. Pan, G., Ni, J., Yu, G., Wei, Y. F., and Dixit, V. M. (1998). TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424:41-45.
5. Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., et al. (2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 26, 7046-7055.
6. Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., et al. (2005). Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 102, 18099-18104.
7. Oberst, A., Pop, C., Tremblay, A. G., Blais, V., Denault, J. B., et al. (2010) Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J. Biol. Chem. 285, 16632-16642.
8. Falschlehner, C., Emmerich, C. H., Gerlach, B., and Walczak, H. (2007) TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 39, 1462-1475.
9. Shirley, S., Morizot, A., and Micheau, O. (2011) Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat. Anticancer Drug Discov. 6, 311-323.
10. Green, D. R., Oberst, A., Dillon, C. P., Weinlich, R., and Salvesen, G. S. (2011) RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol. Cell 44, 9-16.
11. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., et al. (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361.
12. Fox, N. L., Humphreys, R., Luster, T. A., Klein, J., and Gallant, G. (2010) Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert. Opin. Biol. Ther. 10, 1-18.
13. Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009.
14. Modur, V., Nagarajan, R., Evers, B. M., and Milbrandt, J. (2002) FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277, 47928-47937.
15. Koornstra, J. J., Kleibeuker, J. H., van Geelen, C. M., Rijcken, F. E., Hollema, H., et al. (2003) Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. 200, 327-335.
16. Gobbi, G., Di Marcantonio, D., Micheloni, C., Carubbi, C., Galli, D., et al., (2012) TRAIL up-regulation must be accompanied by a reciprocal PKCepsilon down-regulation during differentiation of colonic epithelial cell: implications for colorectal cancer cell differentiation. J. Cell Physiol. 227, 630-638.
17. Finnberg, N., Klein-Szanto, A. J., and El-Deiry, W. S. (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111-123.
18. Kerr, J. F., Winterford, C. M., and Harmon, B. V. (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026.
19. Li, J. and Yuan, J. (2008) Caspases in apoptosis and beyond. Oncogene 27, 6194-6206.
20. Yu, J. and Zhang, L. (2005) The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331, 851-858.
21. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A. et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
22. Papenfuss, K., Cordier, S. M., and Walczak, H. (2008) Death receptors as targets for anti-cancer therapy. J. Cell Mol. Med. 12, 2566-2585.
23. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
24. Pelengaris, S., Khan, M., and Evan, G. I. (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321-334.
25. Hoogwater, F. J., Nijkamp, M. W., Smakman, N., Steller, E. J., Emmink, B. L., et al. (2010) Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138, 2357-2367.
26. Drosopoulos, K. G., Roberts, M. L., Cermak, L., Sasazuki, T., Shirasawa, S. et al. (2005) Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J. Biol. Chem. 280, 22856-22867.
27. Nesterov, A., Nikrad, M., Johnson, T., and Kraft, A. S. (2004) Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 64, 3922-3927.
28. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
29. Makrodouli, E., Oikonomou, E., Koc, M., Andera, L., Sasazuki, T., et al. (2011) BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol. Cancer 10, 118.
30. Smakman, N., Borel Rinkes, I. H., Voest, E. E., and Kranenburg, O. (2005) Control of colorectal metastasis formation by K-Ras. Biochim. Biophys. Acta 1756, 103-114.
31. Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670.
32. LeBlanc, H. N. and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death. Differ. 10, 66-75.
33. Bouralexis, S., Findlay, D. M., Atkins, G. J., Labrinidis, A., Hay, S., et al. (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br. J. Cancer. 89, 206-214.
34. Toscano, F., Fajoui, Z. E., Gay, F., Lalaoui, N., Parmentier, B., et al. (2008) P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene 27, 4161-4171.
35. Sayers, T. J. and Murphy, W. J. (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. 55, 76-84.
36. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821.
37. Kim, K., Fisher, M. J., Xu, S. Q., and el-Deiry, W. S. (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6, 335-346.
38. Lincz, L. F., Yeh, T. X., and Spencer, A. (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15, 1650-1657.
39. Sanlioglu, A. D., Koksal, I. T., Karacay, B., Baykara, M., Luleci, G., et al. (2005) Adenovirus-mediated IKKβKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Therapy. 13, 21-31.
40. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., et al. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195.
41. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., Reed, J. C. (1997). X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304.
42. Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25-35.
43. Morizot, A., Mérino, D., Lalaoui, N., Jacquemin, G., Granci, V., et al. (2011) Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ. 18, 700-711.
44. Jacquemin, G., Granci, V., Gallouet, A. S., Lalaoui, N., Morlé, A., et al. (2012) Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 97, 38-46.
45. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., Sorger, P. K. (2009). Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis Nature 459, 428-432.
46. Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., et al. (2005) Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. 3, 335-343.
47. Chen, C., Edelstein, L. C., and Gelinas, C. (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 20, 2687-2695.
48. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683.
49. Pop, C., Oberst, A., Drag, M., Van Raam, B. J., Riedl, S. J., et al. (2011) FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem. J. 433, 447-457.
50. Budd, R. C., Yeh, W. C., and Tschopp, J. (2006) cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 6, 196-204.
51. Golks, A., Brenner, D., Krammer, P. H., and Lavrik, I. N. (2006) The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J. Exp. Med. 203, 1295-1305.
52. Yang, J. K. (2008) FLIP as an anti-cancer therapeutic target. Yonsei Med. J. 49, 19-27.
53. Nam, S. Y., Jung, G. A., Hur, G. C., Chung, H. Y., Kim, W. H., et al. (2003) Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 94, 1066-1073.
54. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
55. Gillissen, B., Wendt, J., Richter, A., Richter, A., Müer, A., et al. (2010) Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J. Cell Biol. 188, 851-862.
56. Taniai, M., Grambihler, A., Higuchi, H., Werneburg, N., Bronk, S. F., et al. (2004) Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64, 3517-3524.
57. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., et al. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53.
58. Fulda, S., Meyer, E., and Debatin, K. M. (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283-2294.
59. Kandasamy, K., Srinivasula, S. M., Alnemri, E. S., Thompson, C. B., Korsmeyer, S. J., et al. (2003) Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 63, 1712-1721.
60. Xu, J., Zhou, J. Y., Wei, W. Z., and Wu, G. S. (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5, e10226.
61. Kandasamy, K. and Srivastava, R. K. (2002) Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 62, 4929-4937.
62. Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R., et al. (2007) Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J. Biol. Chem. 282, 28189-28194.
63. Shenoy, K., Wu, Y., and Pervaiz, S. (2009) LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 69, 1941-1950.
64. Earel, J. K., Jr., VanOosten, R. L., and Griffith, T. S. (2006) Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66, 499-507.
65. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421.
66. Sinicrope, F. A., Penington, R. C., and Tang, X. M. (2004) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 10, 8284-8292.
67. Burns, T. F. and El-Deiry, W. S. (2001) Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276, 37879-37886.
68. Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25-35.
69. Jin, Z., McDonald, E. R., III, Dicker, D. T., and El-Deiry, W. S. (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279, 35829-35839.
70. Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., et al. (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20, 399 - 403.
71. Garnett, M. J. and Marais, R. (2004) Guilty as charged: BRAF is a human oncogene. Cancer Cell 6, 313-319.
72. Oikonomou, E., Makrodouli, E., Evagelidou, M., Joyce, T., Probert, L., et al. (2009) BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia 11, 1116-1131.
73. Chang, F. and McCubrey, J. A. (2001) P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 20, 4354-4364.
74. Lloyd, A. C., Obermuller, F., Staddon, S., Barth, C. F., McMahon, M., et al. (1997) Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11, 663-677.
75. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
76. Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., et al. (2004) Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5, 501-512.
77. Oikonomou, E., Kosmidou, V., Katseli, A., Kothonidis, K., Mourtzoukou, D., et al. (2009) TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. Int. J. Cancer 125, 2127-2135.
78. Abubaker, J., Bavi, P., Al-Haqawi, W., Sultana, M., Al-Harbi, S., et al. (2009) Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J. Pathol. 219, 435-445.
79. Lievre, A., Bachet, J. B., Le, C. D., Boige, V., Landi, B., et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995.
80. Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851-1857.
81. Welman, A., Burger, M. M., and Hagmann, J. (2000) Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation. Oncogene 19, 4582-4591.
82. Plowman, S. J., Arends, M. J., Brownstein, D. G., Luo, F., Devenney, P. S., et al. (2006) The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Exp. Cell Res. 312, 16-26.
83. Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., et al. (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 24, 8541-8555.
84. Bangert, A., Cristofanon, S., Eckhardt, I., Abhari, B. A., Kolodziej, S., et al. (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 31, 4677-4688
85. Pelengaris, S., Khan, M., and Evan, G. (2002) Review c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764-776
86. Iaccarino, I., Hancock, D., Evan, G., Downward, J. (2003) c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Cell Death Differ. 10, 599-608.
87. Annis, M. G., Soucie, E. L., Dlugosz, P. J., Cruz-Aguado, J. A., Penn, L. Z., et al. (2005) Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 24, 2096-2103.
88. Nieminen, A. I., Partanen, J. I., Hau, A., and Klefstrom, J. (2007) c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis EMBO J. 26, 1055-1067.
89. Rottmann, S., Wang, Y., Nasoff, M., Deveraux, Q. L., and Quon, K. C. (2005) A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc. Natl. Acad. Sci. USA 102, 15195-15200.
90. Chazin, V. R., Kaleko, M., Miller, A. D., and Slamon, D. J. (1992) Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7, 1859-1866.
91. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., et al. (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892-4900.
92. Gibson, S. B. (2004) Epidermal growth factor and trail interactions in epithelial-derived cells. Vitam. Horm. 67, 207-227.
93. Park, S. Y. and Seol, D. W. (2002) Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun. 295, 515-518.
94. Thakkar, H., Chen, X., Tyan, F., Gim, S., Robinson, H., et al. (2001) Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem. 276, 38361-38369.
95. Panner, A., James, C. D., Berger, M. S., and Pieper, R. O. (2005) mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25, 8809-8823.
96. Lee, J. T., Jr., Steelman, L. S., and McCubrey, J. A. (2004) Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 64, 8397-8404.
97. Workman, P. (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10, 47-51.
98. Siegelin, M. D., Habel, A., and Gaiser, T. (2009) 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol. Dis. 33, 243-249.
99. Oikonomou, E., Koc, M., Sourkova, V., Andera, L., and Pintzas, A. (2011) Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS. One. 6, e21632.
100. Vasilevskaya, I. A. and O'Dwyer, P. J. (2005) 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem. Pharmacol. 70, 580-589.
101. Chen, W., Bai, L., Wang, X., Xu, S., Belinsky, S. A., et al. (2010) Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol. Pharmacol. 77, 416-423.
102. Georgakis, G. V., Li, Y., Rassidakis, G. Z., Martinez-Valdez, H., Medeiros, L. J., et al. (2006) Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin. Cancer Res. 12, 584-590.
103. Psahoulia, F. H., Moumtzi, S., Roberts, M. L., Sasazuki, T., Shirasawa, S., et al. (2007) Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 28, 1021-1031.
104. Psahoulia, F. H., Drosopoulos K. G., Doubravska, L., Andera, L. and Pintzas, A. (2007). Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 6, 2591-2599.
105. Zhang, L., Ren, X., Alt, E., Bai, X., Huang, S., et al. (2010) Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464, 1058-1061.
106. Bachireddy, P., Bendapudi, P. K., and Felsher, D. W. (2005) Getting at MYC through RAS. Clin. Cancer Res. 11, 4278-4281.
107. Seki, N., Toh, U., Sayers, T. J., Fujii, T., Miyagi, M., et al. (2010) Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol. Cancer Ther. 9, 1842-1851.
108. Jane, E. P., Premkumar, D. R., and Pollack, I. F. (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 10, 198-208.
109. Zhao, J., Lu, Y., and Shen, H. M. (2012) Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett. 314, 8-23.
110. Song, J. H., Kandasamy, K., and Kraft, A. S. (2008) ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 283, 25003-25013.
111. Ganten, T. M., Haas, T. L., Sykora, J., Stahl, H., Sprick, M. R., et al. (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death. Differ. 11 (Suppl 1), S86-S96.
112. Sayers, T. J., Brooks, A. D., Koh, C. Y., Ma, W., Seki, N., et al. (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102, 303-310.
113. Hougardy, B. M., Maduro, J. H., van der Zee, A. G., de Groot, D.J., van den Heuvel, F. A., et al. (2006) Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int. J. Cancer 118, 1892-1900.
114. Karikari, C. A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., et al. (2007) Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6, 957-966.
115. Hao, J. H., Yu, M., Liu, F. T., Newland, A. C., and Jia, L. (2004) Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 64, 3607-3616.
116. Guo, F., Sigua, C., Tao, J., Bali, P., George, P., et al. (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64, 2580-2589.